reference/24850767

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/24850767

Outgoing Links

Predicate	Object
contentType	Comparative Study\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	941
issn	1470-2045
issueIdentifier	10
pageRange	934-941
publicationName	The Lancet. Oncology
startingPage	934
bibliographicCitation	Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, García-Laraña J, Bengoechea E, Martín A, Mediavilla JD, Palomera L, de Arriba F, González Y, Hernández JM, Sureda A, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paiva B, Montalbán MA, Lahuerta JJ, Bladé J, Miguel JF. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010 Oct;11(10):934–41. doi: 10.1016/s1470-2045(10)70187-x. PMID: 20739218.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_736912cf34d4bce92c24fd097e399a38 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c3651ddef0668f2da02c3b737713cb94 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_77a23d6e2a4856afd804c77c81aa975b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_333924323f6abba50a46be39322f367a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c9bbbc1e6ef39db1a5589baeed68f8cb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1bbd97584cbb86835fa885c9c5147d65 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_335c76e86c9a1ab50f17f149eccb199c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_298b6c1d89296984d93dab4d82a45308 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_82017e7c46472205124a8a8e70a69740 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3f1395b0e350abd0f1fc47ec198eed0a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ac9da75ebb773400fcfcc1274602635e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d3be5a71c7a4d0be482a046dd0c39c40 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_291908a40f0a828453fd82a61ad6f199 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_78463e0f66870f7ad793cd199fb8da8e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_526a07894c72b4fd0b1be2353d86496b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_051b3e39a923309b3c88821f5f07a836 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_812f3ef3a6481069b37f93878e0966b6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_93459e359383b7bdae85a2e31c1d3cf8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_85cd050cbb57cade42bc1bad3fe89386 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f2ab851ed4220e963b1756a77ce0387e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_098b92470d658034a05ece0392448f16 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aac37938a355fdbdc013f19ed1233b0d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cb89e8145b43f5f238d743a516c7ffb6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_abe8efaea0e61d3665807be4593582db http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_99d7e633fecd2a8e917954c22fd3104e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f410e9c638d8d2d0207e20519bc3f422 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eee9ae35f641b229fee069d72c883484 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_381693e97328154aeb28fe4bca229008 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3b9b23061285336472ce323fafb6a35d
date	201010
identifier	https://pubmed.ncbi.nlm.nih.gov/20739218 https://doi.org/10.1016/s1470-2045%2810%2970187-x
isPartOf	https://portal.issn.org/resource/ISSN/1470-2045 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/27004
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
discusses	http://id.nlm.nih.gov/mesh/M0017465 http://id.nlm.nih.gov/mesh/M0021267 http://id.nlm.nih.gov/mesh/M0013330 http://id.nlm.nih.gov/mesh/M0017845 http://id.nlm.nih.gov/mesh/M0350110 http://id.nlm.nih.gov/mesh/M0018225 http://id.nlm.nih.gov/mesh/M0328153 http://id.nlm.nih.gov/mesh/M0002834 http://id.nlm.nih.gov/mesh/M0028268
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D009101Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D009101Q000175 http://id.nlm.nih.gov/mesh/D053208 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D011241Q000008 http://id.nlm.nih.gov/mesh/D013030 http://id.nlm.nih.gov/mesh/D016016 http://id.nlm.nih.gov/mesh/D009101Q000401 http://id.nlm.nih.gov/mesh/D018570 http://id.nlm.nih.gov/mesh/D013997 http://id.nlm.nih.gov/mesh/D012307 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D000367 http://id.nlm.nih.gov/mesh/D013792Q000008 http://id.nlm.nih.gov/mesh/D001897Q000008 http://id.nlm.nih.gov/mesh/D011719Q000008 http://id.nlm.nih.gov/mesh/D011480Q000008 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D018906Q000008 http://id.nlm.nih.gov/mesh/D000069286 http://id.nlm.nih.gov/mesh/D020533Q000008 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D008558Q000008
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID460612 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID387447 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7947 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8530 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8167 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c37c4e80515b927da0969aacdb9547a9 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8854 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5865 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5426

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129356432 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID243055978 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129717275

Total number of triples: 95.